Search results

1

Probiotics, prebiotics and antioxidants as functional foods

100%

Grajek W., Olejnik A., Sip A.

|

2005

|

vol. 52

|

issue 3

665-671

EN

The term "functional foods" comprises some bacterial strains and products of plant and animal origin containing physiologically active compounds beneficial for human health and reducing the risk of chronic diseases. Among the best known functional compounds probiotics, prebiotics and natural antioxidants should be given as examples. These substances can be obtained by biotechnological methods and by extraction from plant or animal tissues.

2

The Metabolic Relationships between Probiotics and Fatty Acids

100%

Dayangaç A., Erdem B.

Acta Physica Polonica A

|

2017

|

vol. 132

|

issue 3

816-818

EN

Probiotics are alive bacteria that have a healthy effect on the hosts and are found in large quantities in the soil and foods. The most recommended probiotics as commercial are the some species of Lactobacillus sp., Bifidobacterium sp., and Streptococcus sp. The fatty acids are formed by the colonic gut flora from dietary fibres, which manage to escape the host's enzymatic digestive systems in the small intestine. Dietary fibres that manage to reach the large intestine are available for several bacterial fermentative reactions. The fermentation of the different dietary fibres leads to an increase in concentrations of several short-chain fatty acids, especially butyrate, propionate and acetate, in the lumen of the proximal regions of the large intestine. In this review, we acquainted that the relationship between fatty acids and probiotic bacteria affects some various health ailments.

3

Probiotic preparation reduces faecal water genotoxicity and cytotoxicity in chickens fed ochratoxin A contaminated feed (in vivo study)

88%

Śliżewska K., Nowak A., Smulikowska S.

|

2016

|

vol. 63

|

issue 2

281-286

EN

The aim of the present study was to assess the genotoxicity and cytotoxicity of the faecal water of chickens fed ochratoxin A (OTA) contaminated feed with and without probiotic preparation. The study was performed on 20 healthy female Ross broiler chickens divided into 4 groups: control chickens - fed with non-supplemented feed; PP chickens - fed feed supplemented with the probiotic preparation; OTA chickens - fed feed contaminated with 1 mg per kg of OTA; OTA + PP chickens - fed feed contaminated with 1 mg per kg of OTA and supplemented with the probiotic preparation. Faecal water samples were collected on the 35th day of life of chickens from each group. Genotoxicity was measured using the comet assay, and cytotoxicity by means of MTT tests. Mean DNA damage, measured as the percentage of DNA in the tails of the comets, was 8.50 ± 1.10 for chickens fed OTA at 1 mg/kg and 6.41 ± 0.67 in the controls. The supplementation of feed with the probiotic preparation decreased the extent of DNA damage to 4.74 ± 0.78. In the control group of chickens the average cytotoxicity was 38.5 ± 0.5 (in MTT), while in the probiotic preparation group (PP group) it was 31.8 ± 0.7 (in MTT). After supplementation of the feed with the probiotic preparation, the genotoxicity and cytotoxicity were decreased in a statistically significant manner.

4

The improvement of treatment efficacy of gastropathy associated with the use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-negative patients with osteoarthritis

88%

Antonenko A. V., Beregova T. V.

Current Issues in Pharmacy and Medical Sciences

|

2014

|

vol. 27

|

issue 4

237-239

EN

Among the more common side effects of osteoarthritis treatment are NSAID-gastropathy and NSAID-enteropathy. NSAIDs can cause direct injury to colon tissue and also impair synthesis of prostaglandins, reduce mucosal integrity, increase permeability and promote an influx of bacteria and toxins. Alterations in gastrointestinal permeability are considered as an initial step in the development of lesions of the gastric mucosa such as erosions and ulcers. The mechanisms underlying the ability of NSAIDs to cause ulceration in the stomach and proximal duodenum are well understood and this injury can be largely be prevented through suppression of gastric acid secretion. However, our work showed that 28-day administration of the anti-secretory preparation pantoprazole (20 mg 2 times per day) resulted in a statistically significant increase of dysbiosis. Monitoring of patients with osteoarthritis who used NSAIDs for more than three months showed that, in comparison to the situation before the beginning of treatment, changes in colonic microbiota were present. Multiprobiotic “Symbiter® acidophilic concentrated” introduced simultaneously with pantoprazole during 20 days prevented formation of dysbiotic changes and led to the quicker healing of gastric mucous healing, in comparison with patients who used only pantoprazole alone. Moreover, it brought about total healing of the gastric mucosa within 4 weeks from the beginning of treatment.

5

Probiotics and prebiotics - renaissance of a therapeutic principle

88%

Fric P.

Open Medicine

|

2007

|

vol. 2

|

issue 3

237-270

EN

Probiotics are nonpathogenic microorganisms mostly of human origin which, when administered in adequate amounts, confer a health benefit on the host and enable to prevent or improve some diseases. Probiotics may be a natural temporary constituent of the resident intestinal microflora, but their concentration is not sufficient for therapeutic purposes. The microbiota, the intestinal epithelium, and the mucosal immune system constitute the gastrointestinal ecosystem. All three components are essential for complete functional and developmental maturity of the system. The viability of intestinal microflora (including probiotic strains) requires the availability of nutritional substrates (prebiotics), i.e. various types of fiber and oligosaccharides. Prebiotics are cleaved by microbial enzymes to numerous substances (short-chain fatty acids, aminoacids, polyamines, growth factors, vitamins and antioxidants) indispensable for metabolic and functional activities of the intestinal mucosa. The principal probiotics in use include lactobacilli, bifidobacteria, some nonpathogenic strains of Escherichia coli, and Saccharomyces boulardii. These microbiota display favourable effects which qualify them for therapeutic use. For this purpose, probiotics have to fulfill a series of requirements verifying their efficacy and safety. Experimental and clinical studies examine the prerequisites for the administration of probiotics in digestive diseases, allergic and atopic affections, as well as in some extraintestinal conditions. Future goals of probiotic application include genomic analysis, controlled postnatal colonisation of the digestive tract, the use of probiotics as carriers of peroral vaccines, and recombinant probiotics with in-situ production and targeted application of therapeutic molecules.

6

Health-promoting properties exhibited by Lactobacillus helveticus strains

88%

Skrzypczak K., Gustaw W., Waśko A.

|

2015

|

vol. 62

|

issue 4

713-720

EN

Many strains belonging to lactobacilli exert a variety of beneficial health effects in humans and some of the bacteria are regarded as probiotic microorganisms. Adherence and capabilities of colonization by Lactobacillus strains of the intestinal tract is a prerequisite for probiotic strains to exhibit desired functional properties. The analysis conducted here aimed at screening strains of Lactobacillus helveticus possessing a health-promoting potential. The molecular analysis performed, revealed the presence of a slpA gene encoding the surface S-layer protein SlpA (contributing to the immunostimulatory activity of L. helveticus M 92 probiotic strain) in all B734, DSM, T80, and T105 strains. The product of gene amplification was also identified in a Bifidobacterium animalis ssp. lactis BB12 probiotic strain. SDS-PAGE of a surface protein extract demonstrated the presence of a protein with a mass of about 50 kDa in all strains, which refers to the mass of the S-layer proteins. These results are confirmed by observations carried with transmission electron microscopy, where a clearly visible S-layer was registered in all the strains analyzed. The in vitro study results obtained indicate that the strongest adhesion capacity to epithelial cells (HT-29) was demonstrated by L. helveticus B734, while coaggregation with pathogens was highly diverse among the tested strains. The percentage degree of coaggregation was increasing with the incubation time. After 5 h of incubation, the strongest ability to coaggregate with Escherichia coli was expressed by T104. The T80 strain demonstrated a significant ability to co-aggregate with Staphylococcus aureus, while DSM with Bacillus subtilis. For B734, the highest values of co-aggregation coefficient was noted in samples with Salmonella. The capability of autoaggregation, antibiotic susceptibility, resistance to increasing salt concentrations, and strain survival in simulated small intestinal juice were also analyzed.

7

Effects of the microencapsulated feed additive of lactic acid bacteria on production parameters and post-vaccinal immune response in pigs

88%

Pomorska-Mól M., Turlewicz-Podbielska H., Wojciechowski J., Pomorska-Mól M., Turlewicz-Podbielska H., Wojciechowski J.

Polish Journal of Veterinary Sciences

|

2021

8

Clinical and microbiological aspects of the use of Lactobacillus rhamnosus PL1 strains in proctological patients with symptoms of chronic proctitis

88%

Borycka-Kiciak K., Strus M., Pietrzak P., Wawiernia K., Mikołajczyk D., Gałęcka M., Heczko P., Tarnowski W.

Polish Journal of Surgery

|

2017

|

vol. 89(3)

16-22

EN

Recurrent proctitis and the symptoms associated therewith pose significant clinical problem in proctological patients. The objective of this study was to assess the impact of the probiotic Lactobacillus rhamnosus PL1 strain on the clinical presentation and composition of intestinal microbiota in patients with symptoms of proctitis in the course of hemorrhoidal disease and diverticulosis. Material consisted of 24 patients in whom no complete clinical improvement could be obtained after the treatment of the underlying disease. Subject to the assessment was the presence and the intensity of clinical symptoms as well as qualitative and quantitative changes in the composition of bacterial flora detected in the stool before, during and after a 9-week supplementation with the probiotic Lactobacillus rhamnosus PL1 strain. Results: In the entire study group, the intensity of pain after 12 weeks was significantly lower (p=0,.011) compared to baseline; the intensity of flatulence and abdominal discomfort was reduced significantly as early as after 3 weeks, with the difference reaching a highly significant level after 12 weeks (pP<0,.0001). No significant difference was observed in the frequency of the reported episodes of diarrhea, constipation, as well as itching and burning in the anal region. As early as after 3 weeks of supplementation with the probiotic L. rhamnosus PL1 strain, significant qualitative and quantitative changes were observed in the composition of intestinal microbiota; the changes differed depending on the underlying disease. An increase in the total counts of the bacteria of Lactobacillus genus, particularly L. rhamnosus PL1 strain was observed regardless of the underlying disease. Conclusion: Tthe probiotic Lactobacillus rhamnosus PL1 strain appears to be useful in restoring appropriate ratios of bacterial populations in patients presenting with symptoms of proctitis in the course of the treatment of certain diseases of the lower gastrointestinal tract.

9

Utilization of Liquid Commercial Probiotics to Improve Survival and Growth of Siamese Catfish Fingerlings (Hypopthalmus pangasionodon (Sauvage, 1878))

75%

Meidi W. S., Lili W., Iskandar I., Suryadi I. B. B.

World News of Natural Sciences

|

2019

|

vol. 24

54-63

EN

The purpose of this research is to determine the effect of liquid commercial probiotics usage on improving the survival rate and growth of Siamese catfish fingerlings. This research was conducted on March to May 2018, at Building 4 Laboratory, Faculty of Fisheries and Marine Sciences, Universitas Padjadjaran. This study used an experimental method with Completely Randomized Design (CRD), which consisted of four treatments and three replications. The treatments are feed without the addition of probiotics, and feed with additional probiotics at doses of 2, 4, and 6 ml / kg of feed. The parameters observed were survival rate, absolute weight, absolute length, feed conversion ratio, proximate test analysis and water quality. Data on absolute weight, absolute length, feed conversion ratio and survival rate were analyzed using analysis of variance, while nutrition changes of fish feed and water quality were analyzed descriptively. The results showed that the best addition of probiotics for feed, is with probiotic doses of 2 ml / kg of feed, which resulted in a 100% survival rate, an absolute weight value of 1.03% and a feed conversion ratio of 1.13.

10

Zastosowanie probiotyków w profilaktyce oraz leczeniu raka żołądka i raka jelita grubego

63%

Kaźmierczak- Siedlecka K. L., Makarewicz W.

Farmacja Polska

|

2020

|

vol. 76

|

issue 2

118-124

EN

The composition of gut microbiota depends on many factors, such as age, life style (eating habits and the level of physical activity), pharmacological treatment (antibiotics, side effects of anti-cancer therapy) as well as surgical procedures. The gut microbiota is involved in carcinogenesis process. Furthermore, gut dysbiosis is described as qualitative and quantitative alterations in gut microbiota and it is observed in cancers. For instance, in patients with colorectal cancer the increased amount of Fusobacterium nucleatum, Bacteroides fragilis, Enterococcus faecalis, Streptococcus bovis as well as Peptostreptococcus anaerobius is noted. It was confirmed that amount of several specific bacteria, such as Lactobacillus, Escherichia-Shigella, Nitrospirae, Burkholderia fungorum and Lachnospiraceae, is increased in patients with gastric cancer. However, the major carcinogen involved in gastric carcinogenesis is Helicobacter pylori; it causes mucosa inflammation, mucosa atrophy, and as a consequence development of gastric cancer. Nowadays, there are several therapeutic methods, which may be used to alter the composition and the activity of gut microbiota. They include administration of probiotic strains, prebiotics, and synbiotics. Probiotics can be used to prevent the development of gastric and colorectal cancer, which was shown in many in vivo and in vitro studies. According to the most recent trials, probiotics reduce the incidence of diarrhoea associated with enteral nutrition. Probiotic strains may also be used as a supportive therapy in treatment of Helicobacter pylori infection. Notwithstanding, they can play a supportive role in standard eradication treatment due to reduction of adverse events of antibiotics. Probiotics decrease the incidence of infections in postooperative period, the frequency of abdominal pain, and radiation-induced diarrhoea. To sum up, probiotics may be used to prevent the development of cancer and they may significantly improve the efficiency of standard anti-cancer therapy.

PL

Mikrobiota przewodu pokarmowego jest modyfikowana przez wiele czynników, w tym styl życia, leczenie farmakologiczne oraz zabiegi chirurgiczne. Dysbioza jelitowa, czyli zaburzenia w składzie i aktywności mikrobioty, może wystąpić w przebiegu chorób nowotworowych. U pacjentów z rakiem jelita grubego obserwuje się zwiększone ilości bakterii – Fusobacterium nucleatum, Bacteroides fragilis, Enterococcus faecalis, Streptococcus bovis oraz Peptostreptococcus anaerobius. Największym karcynogenem raka żołądka jest Helicobacter pylori. Bakteria ta powoduje zapalenie błony śluzowej żołądka prowadząc do jej atrofii, a następnie do rozwinięcia nowotworu. Obecnie znanych jest kilka metod terapeutycznych modyfikujących mikrobiotę przewodu pokarmowego, w tym podaż szczepów probiotycznych, prebiotyków oraz synbiotyków. Probiotyki mogą być stosowane w profilaktyce oraz leczeniu raka żołądka i jelita grubego, co zostało potwierdzone w badaniach in vivo oraz in vitro. Według najnowszych doniesień, probiotyki są skuteczne w zmniejszeniu częstości występowania biegunki będącej skutkiem ubocznym żywienia enteralnego. Dotychczasowe badania potwierdzają także, że szczepy probiotyczne nie mogą być stosowane jako jedyny czynnik eradykacyjny Helicobacter pylori, ale stanowią terapię uzupełniającą podczas standardowego leczenia oraz redukują działania niepożądane antybiotykoterapii. Z kolei u chorych z rakiem jelita grubego probiotyki zmniejszają ryzyko rozwinięcia infekcji pooperacyjnych, bólów brzucha i biegunki związanej z radioterapią. Podsumowując, należy podkreślić, że probiotyki mają zastosowanie na etapie profilaktyki chorób nowotworowych, a także mogą znacząco poprawić wyniki standardowego leczenia przeciwnowotworowego.

11

Ostra biegunka u dzieci

63%

Buda P., Książyk J.

Pediatria i Medycyna Rodzinna

|

2010

|

vol. 6

|

issue 4

275-282

EN

Acute diarrhea is one of the most frequent problems faced by paediatricians. While it usually takes a benign clinical course, on a global scale is still remains one of the leading causes of infantile mortality and is a frequent indication for hospitalisation. Many children are affected, mainly during their first 3 years of life. The commonest type of paediatric acute diarrhea is infective – viral or bacterial (or caused by intoxication by bacterial exotoxins). Rare causes thereof include protozoons, fungi and parasites. The aim of this paper is to review diagnostic and therapeutic approach to paediatric acute diarrhea, based on ESPGHAN and ESPEN 2008 guidelines. Clinical course of acute diarrhea depends mainly on its aetiology. The usual cause of severe diarrhea is rotaviral infection. The principal clinical problem in this setting is dehydration. Its severity is an important prognostic factor and determines the therapeutic approach. First-line treatment includes rehydration by oral route using oral hydrating and hypoosmotic agents. Principles of intravenous rehydration are also discussed. In mild or moderate dehydration, following a brief (4-6 hours) course of intensive rehydration, children should return to their premorbid dietary habits. In most cases, acute infectious diarrhea (both viral and bacterial) resolves spontaneously and does not require, apart from rehydration, any other treatment. The paper presents current ESPGHAN and ESPEN recommendations concerning additional pharmacotherapy and preventive measures.

PL

Ostra biegunka należy do najczęstszych problemów, z jakimi spotyka się pediatra. Mimo że jest to choroba o zwykle łagodnym przebiegu, w skali światowej wciąż pozostaje jedną z głównych przyczyn śmiertelności i jest częstą przyczyną hospitalizacji. Choruje na nią wiele dzieci, zwłaszcza w ciągu pierwszych 3 lat życia. Najczęstszy rodzaj ostrej biegunki u dzieci stanowi biegunka infekcyjna – wirusowa i bakteryjna (lub spowodowana zatruciem egzotoksynami bakterii), rzadziej jest ona wynikiem infekcji wywołanej przez pierwotniaki, grzyby, pasożyty. Celem niniejszej pracy jest przedstawienie postępowania diagnostycznego i leczniczego w ostrej biegunce u dzieci w oparciu o wytyczne ESPGHAN i ESPEN (2008 r.). Przebieg kliniczny zależy głównie od etiologii – najczęstszą przyczyną biegunki o ciężkim przebiegu są zakażenia rotawirusowe. Głównym objawem klinicznym ostrej biegunki jest odwodnienie, jego stopień nasilenia ma charakter rokowniczy i determinuje wybór postępowania. Leczeniem pierwszego wyboru jest nawadnianie doustne za pomocą doustnych płynów nawadniających (DPN) hipoosmolarnych. W poniższym artykule rozszerzono zasady nawadniania dożylnego. W przypadku lekkiego lub umiarkowanego odwodnienia po krótkim (około 4-6-godzinnym) okresie intensywnego nawadniania dzieci powinny być żywione tak jak przed zachorowaniem. W większości przypadków ostra biegunka infekcyjna (zarówno wirusowa, jak i bakteryjna) ustępuje samoistnie i nie wymaga, poza nawadnianiem, dodatkowego leczenia. W pracy przedstawiono aktualne stanowisko ESPGHAN i ESPEN dotyczące dodatkowego postępowania farmakologicznego oraz profilaktyki.

12

Probiotyki i prebiotyki w chorobach przewodu pokarmowego u dzieci

63%

Bąk-Romaniszyn L., Zeman K.

Pediatria i Medycyna Rodzinna

|

2009

|

vol. 5

|

issue 1

16-22

EN

Probiotics are viable microorganisms which being consumed in a proper dose exert beneficial effects on the host. Lactic acid bacteria Lactobacillus and Bifidobacterium and selected strains of Streptococcus, Bacillus, yeast Saccharomyces boulardii are most frequently used as probiotics. Dependently on the strain and the dose probiotic bacteria restore natural properly functioning system of intestinal flora, inhibit the development of numerous pathogenic microorganisms, alleviate the course and shorten the duration of bacterial and viral diarrhoea, prevent the occurrence or relieve antibiotic-associated diarrhoea, eliminate or diminish the symptoms of lactose intolerance as well as normalize intestinal motor activity disorders. Prebiotics are substances contained in food (or added to it) which selectively stimulate the growth and/or activity of some strains of probiotic bacteria found in the alimentary tract. Prebiotics improve the content of intestinal biocenosis, intestinal motor activity, regression of clinical symptoms of intestinal inflammatory diseases and have a beneficial effect on intestinal epithelial cells nourishment by stimulation and creation of conditions for the growth of probiotic strains. Probiotics, prebiotics as well as their combination – synbiotics improve in a natural way by multidirectional therapeutic effect of viable bacterial cultures, our health condition, contribute to pharmacological therapy and are more and more important in modern medicine. The study presents the share of probiotics and prebiotics in the formation of alimentary tract biocenosis and their application in the prophylaxis and treatment of selected gastrointestinal diseases.

PL

Probiotyki to żywe mikroorganizmy, które po spożyciu w odpowiedniej dawce wywierają korzystne działanie na organizm gospodarza. Najczęściej jako probiotyki stosowane są bakterie kwasu mlekowego Lactobacillus i Bifidobacterium oraz wybrane szczepy Streptococcus, Bacillus, jak również drożdże Saccharomyces boulardii. Zależnie od szczepu i dawki bakterie probiotyczne przywracają naturalny, właściwie funkcjonujący układ mikroflory jelitowej, hamują rozwój wielu mikroorganizmów chorobotwórczych, łagodzą przebieg oraz skracają czas trwania niektórych biegunek bakteryjnych i wirusowych, zapobiegają wystąpieniu lub łagodzą przebieg biegunek poantybiotykowych, likwidują lub zmniejszają objawy nietolerancji laktozy, a także normalizują zaburzenia motoryki jelit. Prebiotyki to substancje zawarte w żywności (bądź do niej dodawane), które selektywnie pobudzają wzrost i/lub aktywność wybranych szczepów bakterii probiotycznych obecnych w przewodzie pokarmowym. Prebiotyki przez stymulację i tworzenie warunków dla wzrostu szczepów probiotycznych poprawiają skład biocenozy jelitowej, motorykę jelit, powodują ustąpienie klinicznych objawów chorób zapalnych jelit oraz wpływają korzystnie na odżywienie komórek nabłonka jelitowego. Probiotyki, prebiotyki, jak również ich połączenie – synbiotyki, w sposób naturalny, przez wielokierunkowe oddziaływanie lecznicze żywych kultur baterii, poprawiają stan naszego zdrowia, wspomagają terapie farmakologiczne i mają coraz większe znaczenie w nowoczesnej medycynie. W pracy omówiono udział probiotyków i prebiotyków w kształtowaniu się biocenozy przewodu pokarmowego oraz ich zastosowanie w profilaktyce i leczeniu wybranych chorób przewodu pokarmowego.

13

Rola preparatów osłonowych w farmakoterapii – ocena świadomości pacjentów

63%

Słaby D., Szewczyk S., Beberok A., Wrześniok D. M.

Farmacja Polska

|

2019

|

vol. 75

|

issue 11

591-598

EN

SUBJECT OF THE STUDY: The use of medication is associated with the risk of side effects. In the view of the fact that the consumption of Nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics is growing constantly, it is necessary to apply appropriate protection strategies to prevent side-effects of those drugs. AIM OF THE STUDY: The aim of the study is to asses patients' knowledge about protective agents: drugs that reduce the production of hydrochloric acid from the group of proton pump inhibitors and probiotics in the terms of effectiveness and safety of, respectively, inflammations and the bacterial infections pharmacotherapy. MATERIAL AND METHODS: The research was carried out since October 2018 to February 2019 on the random group of people from Poland, using an original, anonymous questionnaire. The data was collected via Internet and direct contact with the respondents participating classes at the University of Third Age of the Medical University of Silesia. The statistical analysis of the collected results was performed with the use of Microsoft Excel 2010. RESULTS: Almost everyone of the respondents (about 95.0%) think that they understand the concept of a protective agents. Many of them only associates them with antibiotic therapy, not being aware of the broader meaning of this concept. 82.0% of respondents believe that they know the concept of a probiotic, but as many as 64.6 % of patients mistakenly think, that probiotics protect the stomach. About 50.0% of people are aware of the need to protect the stomach with chronic Nonsteroidal anti-inflammatory drugs therapy. CONCLUCIONS: The obtained results show that patients have basic information about gastro-enteroprotective agents (including drugs that reduce the production of hydrochloric acid from the group of proton pump inhibitors and probiotics) however their knowledge is still insufficient to guarantee the effectiveness of therapy. The further education is necessary, which could be improved by introducing the Pharmaceutical Care.

PL

PRZEDMIOT BADAŃ: Stosowanie każdego rodzaju leków wiąże się z ryzykiem wystąpienia działań niepożądanych. W świetle rosnącego spożycia leków przeciwbólowych i antybiotyków konieczne staje się stosowanie właściwych strategii ochronnych, zapobiegających ubocznym skutkom działania tych leków. CEL BADAŃ: Celem pracy jest zbadanie wiedzy pacjentów na temat preparatów osłonowych, w szczególności leków zmniejszających produkcję kwasu solnego z grupy inhibitorów pompy protonowej oraz probiotyków. MATERIAŁ I METODY: Badanie przeprowadzono od października 2018 do lutego 2019 na losowej grupie 582 mieszkańców Polski za pomocą autorskiego, anonimowego kwestionariusza ankiety. Analizę statystyczną zebranego materiału, wykonano za pomocą programu Microsoft Excel 2010. WYNIKI: W badaniu 94,5% ankietowanych zadeklarowało, że rozumie pojęcie preparatu osłonowego. Duży odsetek grupy badanej wiąże je jedynie z antybiotykoterapią, nie mając świadomości szerszego znaczenia tego pojęcia. 82,0% respondentów uważa, że zna pojęcie probiotyku, jednak aż 64,6% z nich niewłaściwie zastosowałoby probiotyk jako osłonę żołądka. Niespełna 50,0% osób ma świadomość konieczności ochrony żołądka przy przewlekłej terapii lekami z grupy niesteroidowych leków przeciwzapalnych. WNIOSKI: Przeprowadzone badanie wykazało, że ankietowani posiadają podstawową wiedzę na temat preparatów osłonowych jednak nie jest ona wystarczająca, by w każdym przypadku zapewnić bezpieczeństwo i skuteczność terapii. Konieczne jest zatem edukacja pacjentów poprzez wdrożenie szeroko dyskutowanej obecnie Opieki Farmaceutycznej.

14

Probiotyki i prebiotyki w profilaktyce i leczeniu chorób u dzieci

51%

Bąk-Romaniszyn L., Zeman K.

Pediatria i Medycyna Rodzinna

|

2010

|

vol. 6

|

issue 3

176-181

EN

Probiotics are viable microorganisms which after consumption, dependently on the strain and dose, exert beneficial effect on the host’s organism. Lactic acid bacteria Lactobacillus and Bifidobacterium and selected strains of Streptococcus, Bacillus as well as Saccharomyces boulardii yeast are most frequently used as probiotics. Probiotics have a favourable effect on the composition of alimentary tract ecological environment demonstrating antagonism in relation to numerous pathogenic microorganisms colonizing gastrointestinal mucosa. The presence of fermentative bacteria in the intestine, mainly lactic acid bacilli, particularly adhesive types prevents from bacterial dislocation and enterotoxemia, normalizes intestinal motor activity disorders and diminishes the symptoms of lactose intolerance. Prebiotics are substances naturally contained in food (or added to it) which selectively stimulate growth and/or activity of some strains of probiotic bacteria found in the alimentary tract. Probiotics and prebiotics as well as their combination – synbiotics are found in food, milk mixtures, pharmacological preparations, food additives, dietary supplements and they improve in a natural way our health condition and are of greater importance in modern medicine. The study presents the share of probiotics and prebiotics in the formation of alimentary tract biocenosis and their application in the prophylaxis and treatment of selected diseases in children, such as: bacterial and viral diarrhoea, antibiotic-induced disbiosis, necrotizing enterocolitis, intestinal colic, non-specific enteritis, alimentary tract dysfunction.

PL

Probiotyki to mikroorganizmy, które wywierają korzystne działanie na organizm gospodarza po spożyciu przez niego odpowiedniej dawki określonego szczepu. Najczęściej jako probiotyki stosowane są bakterie kwasu mlekowego Lactobacillus i Bifidobacterium oraz wybrane szczepy Streptococcus, Bacillus, a także drożdże Saccharomyces boulardii. Probiotyki wpływają korzystnie na skład środowiska ekologicznego przewodu pokarmowego, wykazując antagonizm w stosunku do drobnoustrojów chorobotwórczych kolonizujących błonę śluzową przewodu pokarmowego. Obecność w jelicie bakterii fermentacyjnych, głównie pałeczek kwasu mlekowego, a zwłaszcza typów adhezyjnych, chroni przed dyslokacją bakteryjną i enterotoksemią, normalizuje zaburzenia motoryki jelit i zmniejsza objawy nietolerancji laktozy. Prebiotyki to substancje naturalnie zawarte w żywności (bądź do niej dodawane), które selektywnie pobudzają wzrost i/lub aktywność wybranych szczepów bakterii probiotycznych obecnych w przewodzie pokarmowym. Probiotyki i prebiotyki, jak również ich połączenie – synbiotyki, występują w pożywieniu, mieszankach mlecznych, preparatach farmakologicznych, dodatkach do żywności, suplementach dietetycznych i w sposób naturalny poprawiają stan naszego zdrowia oraz mają coraz większe znaczenie w nowoczesnej medycynie. W pracy omówiono udział probiotyków i prebiotyków w kształtowaniu się biocenozy przewodu pokarmowego oraz w profilaktyce i leczeniu wybranych chorób u dzieci, jak: biegunki bakteryjne i wirusowe, dysbioza poantybiotykowa, martwica jelit noworodków, kolka jelitowa, nieswoiste zapalenia jelit, zaburzenia czynnościowe przewodu pokarmowego.

Refine search results

Probiotics, prebiotics and antioxidants as functional foods

The Metabolic Relationships between Probiotics and Fatty Acids

Probiotic preparation reduces faecal water genotoxicity and cytotoxicity in chickens fed ochratoxin A contaminated feed (in vivo study)

The improvement of treatment efficacy of gastropathy associated with the use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-negative patients with osteoarthritis

Probiotics and prebiotics - renaissance of a therapeutic principle

Health-promoting properties exhibited by Lactobacillus helveticus strains

Effects of the microencapsulated feed additive of lactic acid bacteria on production parameters and post-vaccinal immune response in pigs

Clinical and microbiological aspects of the use of Lactobacillus rhamnosus PL1 strains in proctological patients with symptoms of chronic proctitis

Utilization of Liquid Commercial Probiotics to Improve Survival and Growth of Siamese Catfish Fingerlings (Hypopthalmus pangasionodon (Sauvage, 1878))

Zastosowanie probiotyków w profilaktyce oraz leczeniu raka żołądka i raka jelita grubego

Ostra biegunka u dzieci

Probiotyki i prebiotyki w chorobach przewodu pokarmowego u dzieci

Rola preparatów osłonowych w farmakoterapii – ocena świadomości pacjentów

Probiotyki i prebiotyki w profilaktyce i leczeniu chorób u dzieci